Novo Nordisk in the news

UBS analyst Michael Yee calls Novo Nordisk a "value trap" due to Eli Lilly's current lead in the GLP-1 drug market, though Novo Nordisk is seen as a long-term opportunity for patient investors.

Novo Nordisk lost a key patent for its diabetes and weight-loss drugs Ozempic and Wegovy, potentially shortening market exclusivity to 2031.

Novo Nordisk aims for average growth by 2030, despite strong Q2 2026 results and its leading position in obesity medicines.

Novo Nordisk is replacing its chief legal officer, John Kuckelman, with Thomas Rask Nielsen, causing a change in its top management.

GLP-1 drugs like Ozempic and Mounjaro, made by Novo Nordisk and Eli Lilly, show preliminary evidence of slowing biological aging by several years, in addition to their benefits for weight loss and blood sugar.

Citi Research lowered Novo Nordisk's stock target and future profit forecasts due to anticipated stable margins and increased R&D spending, despite raising Wegovy sales expectations.

Novo Nordisk's stock has dropped 22% this year, leading to mixed analyst opinions with an average price target indicating a potential 23% rise from its current DKK 253.9.

Novo Nordisk introduced a higher-dose semaglutide for type 2 diabetes in Thailand, aiming to provide more treatment options and encourage holistic diabetes care beyond just blood sugar control.

Hackers breached Novo Nordisk systems for over 47 days, stealing AI models and personal data after a USD 25 million ransom was refused.

Novo Nordisk is acquiring new weight-loss and cardiometabolic disease treatments to counter the upcoming patent expiry of semaglutide.

Center for Kvantematematik and Qpurpose are collaborating with Novo Nordisk to research the application of quantum mathematics and quantum computing in healthcare, aiming to solve complex problems and improve lives for people with chronic diseases.

Novo Nordisk stock increased by 1.95% to $38.26, outpacing market declines, yet earnings and revenue are predicted to fall for the upcoming quarter and the full fiscal year.

Novo Nordisk's stock is assessed for undervaluation given its significantly lower P/E ratio compared to industry averages, despite strong clinical data for its semaglutide-based products.

Novo Nordisk's stock has dropped over 70% from its peak due to struggles in the GLP-1 weight-loss drug market, despite its strong revenue and EPS growth over the last five years.

Novo Nordisk is conducting an observational study in Germany to understand adult Hemophilia A patients' preferences for preventive treatment plans, focusing on benefits, risks, and ease of use.

Novo Nordisk's stock has seen a sharp pullback, leading to an undervalued assessment largely based on the projected growth of the GLP-1 market, though risks to this growth exist.

Novo Nordisk's hemophilia A drug, Frehemgo, faces an FDA approval delay due to manufacturing site remediation, despite prior positive international recommendations and no identified drug efficacy or safety concerns.

FDA delays decision on Novo Nordisk's hemophilia drug denecimig, pushing US launch to first half of 2027.

Novo Nordisk is repurchasing B shares as part of a program initiated in May 2026, with DKK 10.25 billion in shares already repurchased by October 2026.

JP Morgan analyst Richard Vosser maintains a Neutral rating and DKK 275 target price for Novo Nordisk A/S.